Remove Clinical Trials Remove Microdosing Remove Safety
article thumbnail

The history and science of psychedelics: from acid and shrooms to ketamine and salvia

The Cannigma

What is microdosing? A microdose is a dose that does not elicit a perceivable intoxicating or trip-like effect. At most, a mood boost should be all that is felt, and if any visual or auditory effects are noticeable then the dose is not, by definition, a microdose. Everyone is different.

History 119
article thumbnail

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Cannabis Law Report

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Oregon proposes only using one type of mushroom for new psilocybin system, and no pills

Cannabis Law Report

There are also draft rules on how facilitators will be trained to sit with people taking psilocybin to ensure safety. For example, there’s a desire among some people to microdose psilocybin, that is taking very small amounts every few days. Other more complicated issues still need to be decided.

article thumbnail

Dispatches from Wonderland Miami

Canna Law Blog

Microdose hosted its annual psychedelics conference in Miami last week (appropriately titled “Wonderland”). Some of these companies are already engaged in clinical trials , a key indicator that significant capital and resources are behind entrants into the market.

article thumbnail

Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

Cannabis Law Report

“Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”.

Therapy 52
article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Rick Doblin, Ph.D, in/rickdoblin/ [link]. a leading biotech company in the hemp and cannabis industries. in/ronanlevy/. The Third Wave.